A Pilot Study to Assess the Effect of Adding 1 Infusion of Human Mesenchymal Stem Cells (hMSC) to Patients Treated With Anti-Amyloid Monoclonal Antibodies Who Are Suffering From Mild Cognitive Impairment or Mild Alzheimer's Disease.

Bernard (Barry) Baumel

Summary

The purpose of this study is to test if adding one infusion of (Human Mesenchymal Stem Cells) hMSCs to the treatment with standard of care (SOC) monoclonal antibodies (mAb) will stabilize the rate of cognitive and functional decline associated with mild Alzheimer's Disease.

Eligibility

Age range: 55–90 years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Adults 55-90 years at the time of signing consent * Patients diagnosed with Mild Cognitive Impairment or mild Dementia due to Alzheimer disease, receiving treatment with an FDA approved monoclonal antibody (Leqembi/Lecanemab or Kisunla/Donanemab) for at least 6 months prior to the infusion visit. * MMSE score 20-26. * Patients must be able to consent. * Have a family member or friend (study partner) who has frequent and sufficient contact with the patient and is able to answer questions about the participant's daily activities to complete the ADCS-MCI-ADL. Completing thi…

Interventions

Biological
human Mesenchymal Stem Cells
Patients eligible to participate will receive one infusion of 25 million cells administered intravenously.

Location

University of Miami Department of Neurology
Miami, Florida
mep980@miami.edu (305) 243-3100

A Pilot Study to Assess the Effect of Adding 1 Infusion of Human Mesenchymal Stem Cells (hMSC) to Patients Treated With Anti-Amyloid Monoclonal Antibodies Who Are Suffering From Mild Cognitive Impairment or Mild Alzheimer's Disease.

Summary

Eligibility

Interventions

Location

Compensation

Run this study?

Details

Conditions